Business · 08/07/2026Updated: 10/17/2026 · 1 min read
FDA Announces Public Advisory Committee Meeting for Replimune's BLA 125827 for Vusolimogene Oderparepvec
Summary
The FDA is hosting a public meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee to provide advice on Replimune's biologics license application (BLA) 125827 for Vusolimogene Oderparepvec, a treatment for certain types of cancer.
Original source language: Federal Register — Health and Human ServicesOpen original release →